Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim's impact on neurological symptoms associated with long COVID Key milestone reached ahead of schedule, with BioVie on track to receive additional $12.6 million of award from the U.S. Department of Defense and initiate the Phase 2 trial Recent Centers for Disease Control and Prevention survey estimated over 5% of U.S. adults currently have long COVID, and ~3.6 million people reported significantly ...

Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim experienced 2 to 4 years age deceleration advantage compared to placebo Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages Bezisterim was associated with 1.5 to 2.3 "fold enrichment" on gene control for hundreds of genes in pathways associated with n ...

CARSON CITY, Nev., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company") today announced that the Company's reverse stock split of its issued and outstanding Class A common stock ("Common Stock"), at an exchange ratio of 1-for-10, is now effective. The Company's Common Stock began trading on a split-adjusted basis and will remain listed on The Nasdaq Capital Market under the symbol "BIVI". The new CUSIP number for the Company's Common Stock following the reverse stock spli ...

CARSON CITY, Nev., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company") today announced that the Company's reverse stock split of its issued and outstanding Class A common stock ("Common Stock"), at an exchange ratio of 1-for-10, is now effective. The Company's Common Stock began trading on a split-adjusted basis and will remain listed on The Nasdaq Capital Market under the symbol "BIVI". The new CUSIP number for the Company's Common Stock following the reverse stock spli ...

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson's disease that helped inform SUNRISE-PD trial design CARSON CITY, Nev., June 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatme ...

CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two poster presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) being held June 21-25, 2024 in Washington, D.C. The presentation Assessment of Bezisterim (NE3107) in Patients with ...

CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two poster presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) being held June 21-25, 2024 in Washington, D.C. The presentation Assessment of Bezisterim (NE3107) in Patients with E ...

CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long ...

Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened Improvements in non-motor symptoms correlated with improvements in motor symptoms for Parkinson’s Disease patients CARSON CITY, Nev., May 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the ...

财务业绩 - 公司在2024年3月31日完成的三个月内净亏损约810万美元，较2023年同期的1500万美元净亏损减少约690万美元[119] - 总运营费用从2023年同期的1380万美元减少至约770万美元，降幅约610万美元[120] - 研发费用从2023年同期的1120万美元减少至约570万美元，降幅约550万美元[121] - 公司在九个月内的净亏损减少约1390万美元[124] - 研发费用减少约400万美元[125,126] - 销售、一般及管理费用减少约280万美元[125,127] - 其他收入净额增加约720万美元[128] 临床试验进展 - 完成阿尔茨海默病III期临床试验、帕金森病II期临床试验以及轻度认知障碍和轻度阿尔茨海默病的临床试验[121] - 暂停了肝硬化腹水II期临床试验，但数据显示治疗组患者腹水较对照组有明显减少[115] 融资情况 - 公司于2024年3月6日完成公开发行,募集资金约2100万美元[131] 持续经营能力 - 公司目前存在持续经营能力的不确定性[132,133] 内部控制 - 公司的披露控制和程序被评估为有效[138] 诉讼情况 - 公司面临一起股东集体诉讼[140,141] - 公司表示该诉讼无实质依据,将积极应诉[142] 管理层情况 - 公司高管和董事未受过任何刑事定罪[143]